These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31034392)

  • 21. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
    Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
    Guglielmetti L; Barkane L; Le Dû D; Marigot-Outtandy D; Robert J; Veziris N; Yazdanpanah Y; Kuksa L; Caumes E; Fréchet-Jachym M
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29419439
    [No Abstract]   [Full Text] [Related]  

  • 25. BPaL approved for multidrug-resistant tuberculosis.
    Burki T
    Lancet Infect Dis; 2019 Oct; 19(10):1063-1064. PubMed ID: 31559963
    [No Abstract]   [Full Text] [Related]  

  • 26. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.
    Kwon YS; Jeon D; Kang H; Yim JJ; Shim TS
    Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33093123
    [No Abstract]   [Full Text] [Related]  

  • 27. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Millard J; Rimmer S; Nimmo C; O'Donnell M
    Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Principles for designing future regimens for multidrug-resistant tuberculosis.
    Brigden G; Nyang'wa BT; du Cros P; Varaine F; Hughes J; Rich M; Horsburgh CR; Mitnick CD; Nuermberger E; McIlleron H; Phillips PP; Balasegaram M
    Bull World Health Organ; 2014 Jan; 92(1):68-74. PubMed ID: 24391302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
    Koirala S; Borisov S; Danila E; Mariandyshev A; Shrestha B; Lukhele N; Dalcolmo M; Shakya SR; Miliauskas S; Kuksa L; Manga S; Aleksa A; Denholm JT; Khadka HB; Skrahina A; Diktanas S; Ferrarese M; Bruchfeld J; Koleva A; Piubello A; Koirala GS; Udwadia ZF; Palmero DJ; Munoz-Torrico M; Gc R; Gualano G; Grecu VI; Motta I; Papavasileiou A; Li Y; Hoefsloot W; Kunst H; Mazza-Stalder J; Payen MC; Akkerman OW; Bernal E; Manfrin V; Matteelli A; Mustafa Hamdan H; Nieto Marcos M; Cadiñanos Loidi J; Cebrian Gallardo JJ; Duarte R; Escobar Salinas N; Gomez Rosso R; Laniado-Laborín R; Martínez Robles E; Quirós Fernandez S; Rendon A; Solovic I; Tadolini M; Viggiani P; Belilovski E; Boeree MJ; Cai Q; Davidavičienė E; Forsman LD; De Los Rios J; Drakšienė J; Duga A; Elamin SE; Filippov A; Garcia A; Gaudiesiute I; Gavazova B; Gayoso R; Gruslys V; Jonsson J; Khimova E; Madonsela G; Magis-Escurra C; Marchese V; Matei M; Moschos C; Nakčerienė B; Nicod L; Palmieri F; Pontarelli A; Šmite A; Souleymane MB; Vescovo M; Zablockis R; Zhurkin D; Alffenaar JW; Caminero JA; Codecasa LR; García-García JM; Esposito S; Saderi L; Spanevello A; Visca D; Tiberi S; Pontali E; Centis R; D'Ambrosio L; van den Boom M; Sotgiu G; Migliori GB
    Pulmonology; 2021; 27(5):403-412. PubMed ID: 33753021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
    Hwang H; Kang H; Kwon YS; Jeon D; Shim TS; Yim JJ
    Clin Infect Dis; 2021 Oct; 73(8):1362-1369. PubMed ID: 33837767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
    Li Y; Sun F; Zhang W
    Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuberculosis treatment and drug regimens.
    Sotgiu G; Centis R; D'ambrosio L; Migliori GB
    Cold Spring Harb Perspect Med; 2015 Jan; 5(5):a017822. PubMed ID: 25573773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA; Scott LJ
    Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
    Furin J; Brigden G; Lessem E; Rich M; Vaughan L; Lynch S
    Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26885674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bedaquiline.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
    [No Abstract]   [Full Text] [Related]  

  • 38. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R; Soni I; Dasgupta A; Chopra S
    Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.
    Holmgaard FB; Guglielmetti L; Lillebaek T; Andersen ÅB; Wejse C; Dahl VN
    Clin Infect Dis; 2023 Apr; 76(7):1328-1337. PubMed ID: 36331978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.